



# Retraction: vitexin attenuates epithelial ovarian cancer cell viability and motility *in vitro* and carcinogenesis *in vivo* via p38 and ERK1/2 pathways related VEGFA

Shuzhen Zhao, Xinlei Guan, Ruijie Hou, Xueying Zhang, Fang Guo, Zhifang Zhang, Caihong Hua

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China

Correspondence to: Caihong Hua. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China. Email: lawrtusdpl@sina.com.

Submitted Oct 27, 2022. Accepted for publication Jul 30, 2024. Published online Aug 19, 2024.

doi: 10.21037/atm-2022-75

View this article at: <https://dx.doi.org/10.21037/atm-2022-75>

Retraction to: Ann Transl Med 2020;8:1139

Recently, we had repeated the related tests and found that the results differed, so the conclusion of the article “Vitexin attenuates epithelial ovarian cancer cell viability and motility *in vitro* and carcinogenesis *in vivo* via p38 and ERK1/2 pathways related VEGFA” (1) published in the Vol 8, No 18 (September 2020) issue of *Annals of Translational Medicine* must have some issues. Therefore, the mentioned article needs to be retracted. All authors agree to retract this paper and understand and appreciate the journal’s retraction policy.

## Footnote

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-2022-75/coif>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Zhao S, Guan X, Hou R, et al. Vitexin attenuates epithelial ovarian cancer cell viability and motility *in vitro* and carcinogenesis *in vivo* via p38 and ERK1/2 pathways related VEGFA. Ann Transl Med 2020;8:1139.

**Cite this article as:** Zhao S, Guan X, Hou R, Zhang X, Guo F, Zhang Z, Hua C. Retraction: vitexin attenuates epithelial ovarian cancer cell viability and motility *in vitro* and carcinogenesis *in vivo* via p38 and ERK1/2 pathways related VEGFA. Ann Transl Med 2024;12(5):107. doi: 10.21037/atm-2022-75